News Release

HYDERABAD, INDIA (13 Aug 2025) -- SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter ended 30 June 2025. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13 Aug 2025 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

	Quarter ended			Year ended
All figures in INR Million except EPS	**30-Jun-25**	**31-Mar-25**	**30-Jun-24**	**31-Mar-25**
Revenue	*24.67*	*26.90*	*50.14*	*175.53*
R&D and Operational expenses	526.15	452.88	315.45	1,724.29
Depreciation and Amortisation	13.68	13.47	14.86	58.22
Finance cost	-	-	0.23	0.47
Total expenses	*539.83*	*466.34*	*330.54*	*1,782.98*
Exceptional items (insurance claim received)	-	-	-	-
Tax	-	-	-	-
Profit/(Loss) After Tax for the period/year	*(515.17)*	*(439.45)*	*(280.40)*	*(1,607.45)*
Other comprehensive income	(0.51)	(5.70)	(0.05)	(5.83)
Total comprehensive income	*(515.68)*	*(445.15)*	*(280.44)*	*(1,613.28)*
Paid up equity capital	218.07	218.07	218.07	218.07
Earnings per share of Rs.1 each (EPS)	*(2.36)*	*(2.02)*	*(1.29)*	*(7.37)*

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer's type dementias in North America and Europe; Patients enrolled crossed 43%. Expected completion by end of FY26.
- SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy in Q2-FY26.
- SUVN-911 (Ropanicant) – Initiated Phase 2B clinical study in USA after successful completion of Phase 2A open label study for Major Depressive Disorder, Enrollment started in July-2025, anticipated to completion FY27.
- SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition, to be initiated during FY26.
- SUVN-I6107 – Ongoing Phase 1 MAD study for establishing safety and pharmacokinetics. Anticipated completion by end of FY26.

(d) The Company has successfully completed its fund raising program to the tune of INR 8576.40 million by issuing 64,002,999 convertible warrants on a preferential basis at an issue price of INR 134/- per warrant payable in tranches. The warrants are convertible into equity shares within a period of 18 months in accordance with the applicable SEBI Regulations.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.